Increased risk of MI with COX-2 inhibitors among patients with history of MI
In a large, population-based, case-control study, rofecoxib and celecoxib were associated with an excess risk of acute myocardial infarction (MI) in patients with a history of MI.
Key Points
Current consensus recommendations from the American Gastroenterology Association suggest that cyclo-oxygenase-2 (COX-2) inhibitors should be avoided in patients at greater risk of cardiovascular events.
The authors stated that this was the first study to adequately assess the risk of cardiovascular side effects associated with COX-2-selective inhibitors in patients with a history of MI.
Upon multivariate logistic regression, current users of rofecoxib were at an increased risk for MI regardless of whether they had a history of MI (RR=1.23; 95% CI, 1.05–1.45 for patients without a history of MI; RR=1.59; 95% CI, 1.15–2.18 for patients with a history of MI; P=.14 for both). In patients with a history of MI, celecoxib increased the risk of MI (RR=1.40; 95% CI, 1.06–1.84; P=.04), but patients without a previous MI did not experience an increased risk with celecoxib (RR=1.03; 95% CI, 0.88–1.20; P=.04). The use of traditional NSAIDs (ie, ibuprofen) or naproxen was not associated with an increased risk of MI, regardless of patient history of MI (RR=1.00; 95% CI, 0.75–1.34, and RR=1.24; 95% CI, 0.83–1.84, respectively). Too few patients received meloxicam to provide an appropriate assessment of its potential for cardiotoxicity.
The authors stated that the mechanism behind the cardiovascular toxicity of COX-2 inhibitors is related to the resulting imbalance between the antiplatelet-aggregating activity of prostacyclin and the proplatelet-aggregating activity of thromboxane that occurs with the use of these specific agents. Rofecoxib causes a more severe imbalance than celecoxib, which, according to the authors, may explain the greater cardiovascular toxicity demonstrated with rofecoxib in this study.
The authors stated that a large, randomized trial could best determine the safety of celecoxib and NSAIDs in this population.
SOURCES
Brophy JM, Lévesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007;93:189–194.
Wilcox CM, Allison J, Benzuly K, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin [erratum in: Clinical Gastroenterol Hepatol. 2006;4:1421]. Clinical Gastroenterol Hepatol. 2006;4:1082–1089.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
